1. Svec, F. and Porter, J. R. The actions of exogenous dehydroepiandrosterone in experimental animals and humans. Proc Soc Exp Biol Med 1998, 218:174-191.

2. Orentreich, N., Brind, J. L., Rizer, R. L., and Vogelman, J. H. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab 1984, 59:551-555.

3. Palmert, M. R., Hayden, D. L., Mansfield, M. J., Crigler, J. F., Jr., Crowley, W. F., Jr., Chandler, D. W., and Boepple, P. A. The longitudinal study of adrenal maturation during gonadal suppression: evidence that adrenarche is a gradual process. J Clin Endocrinol Metab 2001, 86:4536-4542.

4. Reiter, E. O., Fuldauer, V. G., and Root, A. W. Secretion of the adrenal androgen, dehydroepiandrosterone sulfate, during normal infancy, childhood, and adolescence, in sick infants, and in children with endocrinologic abnormalities. J Pediatr 1977, 90:766-770.

5. Sklar, C. A., Kaplan, S. L., and Grumbach, M. M. Evidence for dissociation between adrenarche and gonadarche: studies in patients with idiopathic precocious puberty, gonadal dysgenesis, isolated gonadotropin deficiency, and constitutionally delayed growth and adolescence. J Clin Endocrinol Metab 1980, 51:548-556.

6. Orentreich, N., Brind, J. L., Vogelman, J. H., Andres, R., and Baldwin, H. Long-term longitudinal measurements of plasma dehydroepiandrosterone sulfate in normal men. J Clin Endocrinol Metab 1992, 75:1002-1004.

7. Laughlin, G. A. and Barrett-Connor, E. Sexual dimorphism in the influence of advanced aging on adrenal hormone levels: the Rancho Bernardo Study. J Clin Endocrinol Metab 2000, 85:3561-3568.

8. Parker, C. R., Jr., Mixon, R. L., Brissie, R. M., and Grizzle, W. E. Aging alters zonation in the adrenal cortex of men. J Clin Endocrinol Metab 1997, 82:3898-3901.

9. Liu, C. H., Laughlin, G. A., Fischer, U. G., and Yen, S. S. Marked attenuation of ultradian and circadian rhythms of dehydroepiandrosterone in postmenopausal women: evidence for a reduced 17,20-desmolase enzymatic activity. J Clin Endocrinol Metab 1990, 71:900-906.

10. Parker, C. R., Jr., Slayden, S. M., Azziz, R., Crabbe, S. L., Hines, G. A., Boots, L. R., and Bae, S. Effects of aging on adrenal function in the human: responsiveness and sensitivity of adrenal androgens and cortisol to adrenocorticotropin in premenopausal and postmenopausal women. J Clin Endocrinol Metab 2000, 85:48-54.

11. Khaw, K. T. Dehydroepiandrosterone, dehydroepiandrosterone sulphate and cardiovascular disease. J Endocrinol 1996, 150 Suppl:S149-S153.

12. Thomas, G., Frenoy, N., Legrain, S., Sebag-Lanoe, R., Baulieu, E. E., and Debuire, B. Serum dehydroepiandrosterone sulfate levels as an individual marker. J Clin Endocrinol Metab 1994, 79:1273-1276.

13. Arlt, W., Justl, H. G., Callies, F., Reincke, M., Hubler, D., Oettel, M., Ernst, M., Schulte, H. M., and Allolio, B. Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. J Clin Endocrinol Metab 1998, 83:1928-1934.

14. Arlt, W., Haas, J., Callies, F., Reincke, M., Hubler, D., Oettel, M., Ernst, M., Schulte, H. M., and Allolio, B. Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. J Clin Endocrinol Metab 1999, 84:2170-2176.

15. Labrie, F., Belanger, A., Cusan, L., and Candas, B. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology. J Clin Endocrinol Metab 1997, 82:2403-2409.

16. Giagulli, V. A., Verdonck, L., Giorgino, R., and Vermeulen, A. Precursors of plasma androstanediol- and androgen-glucuronides in women. J Steroid Biochem 1989, 33:935-940.

17. Allolio, B. and Arlt, W. DHEA treatment: myth or reality? Trends Endocrinol Metab 2002, 13:288-294.

18. Martel, C., Melner, M. H., Gagne, D., Simard, J., and Labrie, F. Widespread tissue distribution of steroid sulfatase, 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase (3 beta-HSD), 17 beta-HSD 5 alpha-reductase and aromatase activities in the rhesus monkey. Mol Cell Endocrinol 1994, 104:103-111.

19. Jakob, F., Siggelkow, H., Homann, D., Kohrle, J., Adamski, J., and Schutze, N. Local estradiol metabolism in osteoblast- and osteoclast-like cells. J Steroid Biochem Mol Biol 1997, 61:167-174.

20. English, M. A., Hughes, S. V., Kane, K. F., Langman, M. J., Stewart, P. M., and Hewison, M. Oestrogen inactivation in the colon: analysis of the expression and regulation of 17beta-hydroxysteroid dehydrogenase isozymes in normal colon and colonic cancer. Br J Cancer 2000, 83:550-558.

21. Labrie, F. Intracrinology. Mol Cell Endocrinol 1991, 78:C113-C118.

22. Bird, C. E., Masters, V., and Clark, A. F. Dehydroepiandrosterone sulfate: kinetics of metabolism in normal young men and women. Clin Invest Med 1984, 7:119-122.

23. Corpechot, C., Robel, P., Axelson, M., Sjovall, J., and Baulieu, E. E. Characterization and measurement of dehydroepiandrosterone sulfate in rat brain. Proc Natl Acad Sci U S A 1981, 78:4704-4707.

24. Compagnone, N. A., Bulfone, A., Rubenstein, J. L., and Mellon, S. H. Steroidogenic enzyme P450c17 is expressed in the embryonic central nervous system. Endocrinology 1995, 136:5212-5223.

25. Zwain, I. H. and Yen, S. S. Neurosteroidogenesis in astrocytes, oligodendrocytes, and neurons of cerebral cortex of rat brain. Endocrinology 1999, 140:3843-3852.

26. Bergeron, R., de Montigny, C., and Debonnel, G. Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors. J Neurosci 1996, 16:1193-1202.

27. Majewska, M. D., Demirgoren, S., Spivak, C. E., and London, E. D. The neurosteroid dehydroepiandrosterone sulfate is an allosteric antagonist of the GABAA receptor. Brain Res 1990, 526:143-146.

28. Demirgoren, S., Majewska, M. D., Spivak, C. E., and London, E. D. Receptor binding and electrophysiological effects of dehydroepiandrosterone sulfate, an antagonist of the GABAA receptor. Neuroscience 1991, 45:127-135.

29. Compagnone, N. A. and Mellon, S. H. Dehydroepiandrosterone: a potential signalling molecule for neocortical organization during development. Proc Natl Acad Sci U S A 1998, 95:4678-4683.

30. Meikle, A. W., Dorchuck, R. W., Araneo, B. A., Stringham, J. D., Evans, T. G., Spruance, S. L., and Daynes, R. A. The presence of a dehydroepiandrosterone-specific receptor binding complex in murine T cells. J Steroid Biochem Mol Biol 1992, 42:293-304.

31. Okabe, T., Haji, M., Takayanagi, R., Adachi, M., Imasaki, K., Kurimoto, F., Watanabe, T., and Nawata, H. Up-regulation of high-affinity dehydroepiandrosterone binding activity by dehydroepiandrosterone in activated human T lymphocytes. J Clin Endocrinol Metab 1995, 80:2993-2996.

32. Liu, D. and Dillon, J. S. Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(i2,3). J Biol Chem 2002, 277:21379-21388.

33. Simoncini, T., Mannella, P., Fornari, L., Varone, G., Caruso, A., and Genazzani, A. R. Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms. Endocrinology 2003, 144:3449-3455.

34. Williams, M. R., Ling, S., Dawood, T., Hashimura, K., Dai, A., Li, H., Liu, J. P., Funder, J. W., Sudhir, K., and Komesaroff, P. A. Dehydroepiandrosterone inhibits human vascular smooth muscle cell proliferation independent of ARs and ERs. J Clin Endocrinol Metab 2002, 87:176-181.

35. Kicman, A. T., Bassindale, T., Cowan, D. A., Dale, S., Hutt, A. J., and Leeds, A. R. Effect of androstenedione ingestion on plasma testosterone in young women; a dietary supplement with potential health risks. Clin Chem 2003, 49:167-169.

36. King, D. S., Sharp, R. L., Vukovich, M. D., Brown, G. A., Reifenrath, T. A., Uhl, N. L., and Parsons, K. A. Effect of oral androstenedione on serum testosterone and adaptations to resistance training in young men: a randomized controlled trial. JAMA 1999, 281:2020-2028.

37. Brown, G. A., Vukovich, M. D., Martini, E. R., Kohut, M. L., Franke, W. D., Jackson, D. A., and King, D. S. Endocrine responses to chronic androstenedione intake in 30- to 56-year-old men. J Clin Endocrinol Metab 2000, 85:4074-4080.

38. Leder, B. Z., Longcope, C., Catlin, D. H., Ahrens, B., Schoenfeld, D. A., and Finkelstein, J. S. Oral androstenedione administration and serum testosterone concentrations in young men. JAMA 2000, 283:779-782.

39. Leder, B. Z., Catlin, D. H., Longcope, C., Ahrens, B., Schoenfeld, D. A., and Finkelstein, J. S. Metabolism of orally administered androstenedione in young men. J Clin Endocrinol Metab 2001, 86:3654-3658.

40. Barrett-Connor, E., Khaw, K. T., and Yen, S. S. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med 1986, 315:1519-1524.

41. Barrett-Connor, E. and Khaw, K. T. Absence of an inverse relation of dehydroepiandrosterone sulfate with cardiovascular mortality in postmenopausal women. N Engl J Med 1987, 317:711-

42. Barrett-Connor, E. and Goodman-Gruen, D. Dehydroepiandrosterone sulfate does not predict cardiovascular death in postmenopausal women. The Rancho Bernardo Study. Circulation 1995, 91:1757-1760.

43. Berr, C., Lafont, S., Debuire, B., Dartigues, J. F., and Baulieu, E. E. Relationships of dehydroepiandrosterone sulfate in the elderly with functional, psychological, and mental status, and short-term mortality: a French community-based study. Proc Natl Acad Sci U S A 1996, 93:13410-13415.

44. Trivedi, D. P. and Khaw, K. T. Dehydroepiandrosterone sulfate and mortality in elderly men and women. J Clin Endocrinol Metab 2001, 86:4171-4177.

45. Mazat, L., Lafont, S., Berr, C., Debuire, B., Tessier, J. F., Dartigues, J. F., and Baulieu, E. E. Prospective measurements of dehydroepiandrosterone sulfate in a cohort of elderly subjects: relationship to gender, subjective health, smoking habits, and 10-year mortality. Proc Natl Acad Sci U S A 2001, 98:8145-8150.

46. Ravaglia, G., Forti, P., Maioli, F., Boschi, F., Bernardi, M., Pratelli, L., Pizzoferrato, A., and Gasbarrini, G. The relationship of dehydroepiandrosterone sulfate (DHEAS) to endocrine-metabolic parameters and functional status in the oldest-old. Results from an Italian study on healthy free-living over-ninety-year-olds. J Clin Endocrinol Metab 1996, 81:1173-1178.

47. Deighton, C. M., Watson, M. J., and Walker, D. J. Sex hormones in postmenopausal HLA-identical rheumatoid arthritis discordant sibling pairs. J Rheumatol 1992, 19:1663-1667.

48. Parker, L. N., Levin, E. R., and Lifrak, E. T. Evidence for adrenocortical adaptation to severe illness. J Clin Endocrinol Metab 1985, 60:947-952.

49. Lovas, K., Loge, J. H., and Husebye, E. S. Subjective health status in Norwegian patients with Addison's disease. Clin Endocrinol (Oxf) 2002, 56:581-588.

50. Gurnell, E. M., Hunt, P. J., Curran, S. E., Conway, C. L., Huppert, F. A., Herbert, J., and Chatterjee, V. K. A longer term trial of DHEA replacement in Addison's disease. Endocrine Abstracts 2002, 4:OC-24-

51. Jakobi, J. M., Killinger, D. W., Wolfe, B. M., Mahon, J. L., and Rice, C. L. Quadriceps muscle function and fatigue in women with Addison's disease. Muscle Nerve 2001, 24:1040-1049.

52. Arlt, W., Callies, F., van Vlijmen, J. C., Koehler, I., Reincke, M., Bidlingmaier, M., Huebler, D., Oettel, M., Ernst, M., Schulte, H. M., and Allolio, B. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med 1999, 341:1013-1020.

53. Hunt, P. J., Gurnell, E. M., Huppert, F. A., Richards, C., Prevost, A. T., Wass, J. A., Herbert, J., and Chatterjee, V. K. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. J Clin Endocrinol Metab 2000, 85:4650-4656.

54. Young, J., Couzinet, B., Nahoul, K., Brailly, S., Chanson, P., Baulieu, E. E., and Schaison, G. Panhypopituitarism as a model to study the metabolism of dehydroepiandrosterone (DHEA) in humans. J Clin Endocrinol Metab 1997, 82:2578-2585.

55. Arlt, W. Management of the androgen-deficient woman. Growth Horm IGF Res 2003, 13 Suppl:S85-S89.

56. Johannsson, G., Burman, P., Wiren, L., Engstrom, B. E., Nilsson, A. G., Ottosson, M., Jonsson, B., Bengtsson, B. A., and Karlsson, F. A. Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. J Clin Endocrinol Metab 2002, 87:2046-2052.

57. Lovas, K., Gebre-Medhin, G., Trovik, T. S., Fougner, K. J., Uhlving, S., Nedrebo, B. G., Myking, O. L., Kampe, O., and Husebye, E. S. Replacement of dehydroepiandrosterone in adrenal failure: no benefit for subjective health status and sexuality in a 9-month, randomized, parallel group clinical trial. J Clin Endocrinol Metab 2003, 88:1112-1118.

58. Callies, F., Fassnacht, M., van Vlijmen, J. C., Koehler, I., Huebler, D., Seibel, M. J., Arlt, W., and Allolio, B. Dehydroepiandrosterone replacement in women with adrenal insufficiency: effects on body composition, serum leptin, bone turnover, and exercise capacity. J Clin Endocrinol Metab 2001, 86:1968-1972.

59. Arlt, W. and Allolio, B. DHEA replacement in adrenal insufficiency. J Clin Endocrinol Metab 2003, 88:4001-4002.

60. Morales, A. J., Nolan, J. J., Nelson, J. C., and Yen, S. S. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994, 78:1360-1367.

61. Wolf, O. T., Neumann, O., Hellhammer, D. H., Geiben, A. C., Strasburger, C. J., Dressendorfer, R. A., Pirke, K. M., and Kirschbaum, C. Effects of a two-week physiological dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly women and men. J Clin Endocrinol Metab 1997, 82:2363-2367.

62. Wolf, O. T., Naumann, E., Hellhammer, D. H., and Kirschbaum, C. Effects of dehydroepiandrosterone replacement in elderly men on event-related potentials, memory, and well-being. J Gerontol A Biol Sci Med Sci 1998, 53:M385-M390.

63. Arlt, W., Callies, F., Koehler, I., van Vlijmen, J. C., Fassnacht, M., Strasburger, C. J., Seibel, M. J., Huebler, D., Ernst, M., Oettel, M., Reincke, M., Schulte, H. M., and Allolio, B. Dehydroepiandrosterone supplementation in healthy men with an age-related decline of dehydroepiandrosterone secretion. J Clin Endocrinol Metab 2001, 86:4686-4692.

64. Van Niekerk, J. K., Huppert, F. A., and Herbert, J. Salivary cortisol and DHEA: association with measures of cognition and well-being in normal older men, and effects of three months of DHEA supplementation. Psychoneuroendocrinology 2001, 26:591-612.

65. Flynn, M. A., Weaver-Osterholtz, D., Sharpe-Timms, K. L., Allen, S., and Krause, G. Dehydroepiandrosterone replacement in aging humans. J Clin Endocrinol Metab 1999, 84:1527-1533.

66. Baulieu, E. E., Thomas, G., Legrain, S., Lahlou, N., Roger, M., Debuire, B., Faucounau, V., Girard, L., Hervy, M. P., Latour, F., Leaud, M. C., Mokrane, A., Pitti-Ferrandi, H., Trivalle, C., de Lacharriere, O., Nouveau, S., Rakoto-Arison, B., Souberbielle, J. C., Raison, J., Le Bouc, Y., Raynaud, A., Girerd, X., and Forette, F. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci U S A 2000, 97:4279-4284.

67. Wolkowitz, O. M., Reus, V. I., Keebler, A., Nelson, N., Friedland, M., Brizendine, L., and Roberts, E. Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry 1999, 156:646-649.

68. Bloch, M., Schmidt, P. J., Danaceau, M. A., Adams, L. F., and Rubinow, D. R. Dehydroepiandrosterone treatment of midlife dysthymia. Biol Psychiatry 1999, 45:1533-1541.

69. Sugino, M., Ohsawa, N., Ito, T., Ishida, S., Yamasaki, H., Kimura, F., and Shinoda, K. A pilot study of dehydroepiandrosterone sulfate in myotonic dystrophy. Neurology 1998, 51:586-589.

70. Strous, R. D., Maayan, R., Lapidus, R., Stryjer, R., Lustig, M., Kotler, M., and Weizman, A. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch Gen Psychiatry 2003, 60:133-141.

71. Reiter, W. J., Pycha, A., Schatzl, G., Pokorny, A., Gruber, D. M., Huber, J. C., and Marberger, M. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology 1999, 53:590-594.

72. Wolkowitz, O. M., Kramer, J. H., Reus, V. I., Costa, M. M., Yaffe, K., Walton, P., Raskind, M., Peskind, E., Newhouse, P., Sack, D., De Souza, E., Sadowsky, C., and Roberts, E. DHEA treatment of Alzheimer's disease: a randomized, double-blind, placebo-controlled study. Neurology 2003, 60:1071-1076.

73. Van Vollenhoven, R. F., Engleman, E. G., and McGuire, J. L. Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheum 1995, 38:1826-1831.

74. Petri, M. A., Lahita, R. G., Van Vollenhoven, R. F., Merrill, J. T., Schiff, M., Ginzler, E. M., Strand, V., Kunz, A., Gorelick, K. J., and Schwartz, K. E. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2002, 46:1820-1829.

75. Chang, D. M., Lan, J. L., Lin, H. Y., and Luo, S. F. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46:2924-2927.

76. Lahita, R. G., Bradlow, H. L., Ginzler, E., Pang, S., and New, M. Low plasma androgens in women with systemic lupus erythematosus. Arthritis Rheum 1987, 30:241-248.

77. Melez, K. A., Boegel, W. A., and Steinberg, A. D. Therapeutic studies in New Zealand mice. VII. Successful androgen treatment of NZB/NZW F1 females of different ages. Arthritis Rheum 1980, 23:41-47.

78. Van Vollenhoven, R. F., Engleman, E. G., and McGuire, J. L. An open study of dehydroepiandrosterone in systemic lupus erythematosus. Arthritis Rheum 1994, 37:1305-1310.

79. Andus, T., Klebl, F., Rogler, G., Bregenzer, N., Scholmerich, J., and Straub, R. H. Patients with refractory Crohn's disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study. Aliment Pharmacol Ther 2003, 17:409-414.

80. Evans, T. G., Judd, M. E., Dowell, T., Poe, S., Daynes, R. A., and Araneo, B. A. The use of oral dehydroepiandrosterone sulfate as an adjuvant in tetanus and influenza vaccination of the elderly. Vaccine 1996, 14:1531-1537.

81. Danenberg, H. D., Ben Yehuda, A., Zakay-Rones, Z., Gross, D. J., and Friedman, G. Dehydroepiandrosterone treatment is not beneficial to the immune response to influenza in elderly subjects. J Clin Endocrinol Metab 1997, 82:2911-2914.

82. Degelau, J., Guay, D., and Hallgren, H. The effect of DHEAS on influenza vaccination in aging adults. J Am Geriatr Soc 1997, 45:747-751.

83. Rasmussen, B. B., Volpi, E., Gore, D. C., and Wolfe, R. R. Androstenedione does not stimulate muscle protein anabolism in young healthy men. J Clin Endocrinol Metab 2000, 85:55-59.

84. Kline, M. D. and Jaggers, E. D. Mania onset while using dehydroepiandrosterone. Am J Psychiatry 1999, 156:971-

85. Markowitz, J. S., Carson, W. H., and Jackson, C. W. Possible dihydroepiandrosterone-induced mania. Biol Psychiatry 1999, 45:241-242.

86. Arlt, W., Callies, F., and Allolio, B. DHEA replacement in women with adrenal insufficiency--pharmacokinetics, bioconversion and clinical effects on well-being, sexuality and cognition. Endocr Res 2000, 26:505-511.

87. Shifren, J. L., Braunstein, G. D., Simon, J. A., Casson, P. R., Buster, J. E., Redmond, G. P., Burki, R. E., Ginsburg, E. S., Rosen, R. C., Leiblum, S. R., Caramelli, K. E., and Mazer, N. A. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000, 343:682-688.

88. Labrie, F., Luu-The, V., Labrie, C., Belanger, A., Simard, J., Lin, S. X., and Pelletier, G. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 2003, 24:152-182.

89. Morales, A. J., Haubrich, R. H., Hwang, J. Y., Asakura, H., and Yen, S. S. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol (Oxf) 1998, 49:421-432.

90. Yen, S. S., Morales, A. J., and Khorram, O. Replacement of DHEA in aging men and women. Potential remedial effects. Ann N Y Acad Sci 1995, 774:128-142.

91. Casson, P. R., Faquin, L. C., Stentz, F. B., Straughn, A. B., Andersen, R. N., Abraham, G. E., and Buster, J. E. Replacement of dehydroepiandrosterone enhances T-lymphocyte insulin binding in postmenopausal women. Fertil Steril 1995, 63:1027-1031.

92. Diamond, P., Cusan, L., Gomez, J. L., Belanger, A., and Labrie, F. Metabolic effects of 12-month percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women. J Endocrinol 1996, 150 Suppl:S43-S50.

93. Kawano, H., Yasue, H., Kitagawa, A., Hirai, N., Yoshida, T., Soejima, H., Miyamoto, S., Nakano, M., and Ogawa, H. Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. J Clin Endocrinol Metab 2003, 88:3190-3195.

94. Percheron, G., Hogrel, J. Y., Denot-Ledunois, S., Fayet, G., Forette, F., Baulieu, E. E., Fardeau, M., and Marini, J. F. Effect of 1-year oral administration of dehydroepiandrosterone to 60- to 80-year-old individuals on muscle function and cross-sectional area: a double-blind placebo-controlled trial. Arch Intern Med 2003, 163:720-727.

95. Villareal, D. T., Holloszy, J. O., and Kohrt, W. M. Effects of DHEA replacement on bone mineral density and body composition in elderly women and men. Clin Endocrinol (Oxf) 2000, 53:561-568.

96. Casson, P. R., Santoro, N., Elkind-Hirsch, K., Carson, S. A., Hornsby, P. J., Abraham, G., and Buster, J. E. Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: a six-month trial. Fertil Steril 1998, 70:107-110.

97. Labrie, F., Diamond, P., Cusan, L., Gomez, J. L., Belanger, A., and Candas, B. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab 1997, 82:3498-3505.

98. Kahn, A. J. and Halloran, B. Dehydroepiandrosterone supplementation and bone turnover in middle-aged to elderly men. J Clin Endocrinol Metab 2002, 87:1544-1549.

99. Suzuki, T., Suzuki, N., Daynes, R. A., and Engleman, E. G. Dehydroepiandrosterone enhances IL2 production and cytotoxic effector function of human T cells. Clin Immunol Immunopathol 1991, 61:202-211.

100. Solerte, S. B., Fioravanti, M., Vignati, G., Giustina, A., Cravello, L., and Ferrari, E. Dehydroepiandrosterone sulfate enhances natural killer cell cytotoxicity in humans via locally generated immunoreactive insulin-like growth factor I. J Clin Endocrinol Metab 1999, 84:3260-3267.

101. Gordon, C. M., LeBoff, M. S., and Glowacki, J. Adrenal and gonadal steroids inhibit IL-6 secretion by human marrow cells. Cytokine 2001, 16:178-186.

102. Straub, R. H., Konecna, L., Hrach, S., Rothe, G., Kreutz, M., Scholmerich, J., Falk, W., and Lang, B. Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: possible link between endocrinosenescence and immunosenescence. J Clin Endocrinol Metab 1998, 83:2012-2017.

103. Suzuki, T., Suzuki, N., Engleman, E. G., Mizushima, Y., and Sakane, T. Low serum levels of dehydroepiandrosterone may cause deficient IL-2 production by lymphocytes in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1995, 99:251-255.

104. Oelkers, W. Dehydroepiandrosterone for adrenal insufficiency. N Engl J Med 1999, 341:1073-1074.

105. Arlt, W. and Allolio, B. Adrenal insufficiency. Lancet 2003, 361:1881-1893.

106. Achermann, J. C. and Silverman, B. L. Dehydroepiandrosterone replacement for patients with adrenal insufficiency. Lancet 2001, 357:1381-1382.